CATALYST BIOSCIENCES INC (CBIO)
US14888D2080 - Common Stock
Overall CBIO gets a fundamental rating of 1 out of 10. We evaluated CBIO against 588 industry peers in the Biotechnology industry. While CBIO seems to be doing ok healthwise, there are quite some concerns on its profitability. CBIO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CBIO has reported negative net income.
In the past year CBIO has reported a negative cash flow from operations.
CBIO had negative earnings in each of the past 5 years.
CBIO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CBIO has a worse Return On Assets (-444.02%) than 97.85% of its industry peers.
CBIO has a worse Return On Equity (-1257.95%) than 85.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -444.02% | ||
| ROE | -1257.95% | ||
| ROIC | N/A |
ROA(3y)-82.09%
ROA(5y)-65.26%
ROE(3y)-119.61%
ROE(5y)-92.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CBIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
CBIO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CBIO has more shares outstanding
There is no outstanding debt for CBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CBIO has an Altman-Z score of -60.55. This is a bad value and indicates that CBIO is not financially healthy and even has some risk of bankruptcy.
CBIO has a Altman-Z score of -60.55. This is amonst the worse of the industry: CBIO underperforms 97.52% of its industry peers.
CBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -60.55 |
ROIC/WACCN/A
WACC10.5%
2.3 Liquidity
CBIO has a Current Ratio of 2.88. This indicates that CBIO is financially healthy and has no problem in meeting its short term obligations.
CBIO's Current ratio of 2.88 is on the low side compared to the rest of the industry. CBIO is outperformed by 72.44% of its industry peers.
A Quick Ratio of 2.88 indicates that CBIO has no problem at all paying its short term obligations.
CBIO's Quick ratio of 2.88 is on the low side compared to the rest of the industry. CBIO is outperformed by 71.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.88 | ||
| Quick Ratio | 2.88 |
3. Growth
3.1 Past
CBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -465.60%.
CBIO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
CBIO shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.89% yearly.
EPS 1Y (TTM)-465.6%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-556.25%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y-4.89%
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to decrease by -26.45% on average over the next years. This is quite bad
CBIO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y-117.39%
EPS Next 2Y-42.57%
EPS Next 3Y-26.45%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CBIO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as CBIO's earnings are expected to decrease with -26.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.57%
EPS Next 3Y-26.45%
5. Dividend
5.1 Amount
No dividends for CBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CATALYST BIOSCIENCES INC
NASDAQ:CBIO (10/30/2023, 8:00:01 PM)
After market: 0.5406 +0.03 (+5.73%)0.5113
-0.01 (-2.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap19.42M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -444.02% | ||
| ROE | -1257.95% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.88 | ||
| Quick Ratio | 2.88 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-465.6%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-117.39%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y